International Stem Cell Corp. (ISCO) Publishes Results from Preclinical Study of ISC-hpNSC® for Treatment of Parkinson’s Disease
Before the opening bell, International Stem Cell Corp. (OTCQB: ISCO) announced the publication of results from a 12-month preclinical, non-human primate study. The data highlights the safety and efficacy of ISCO’s proprietary human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC®) for the treatment of Parkinson’s disease. According to the results of this study, transplantation of the neural cells was both safe and well tolerated by non-human primates, with the animals demonstrating no serious adverse events throughout the 12-month trial. “The publication of the data in the peer-reviewed and highly-respected journal, Cell Transplantation, brings to conclusion the preclinical stage of ISCO's…